Gilead Raises HIV Franchise Prices
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK also initiates price increase for its HIV drugs.
You may also be interested in...
Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.